

BMJ Open Loss of GD1-positive *Lactobacillus* correlates with inflammation in human lungs with COPD

Marc A Sze,¹ Soraya Utokaparch,¹ W Mark Elliott,¹ James C Hogg,¹ Richard G Hegele²

To cite: Sze MA, Utokaparch S, Elliott WM, et al. Loss of GD1-positive *Lactobacillus* correlates with inflammation in human lungs with COPD. *BMJ Open* 2015;5:e006677. doi:10.1136/bmjopen-2014-006677

► Prepublication history and additional material is available. To view please visit the journal (<http://dx.doi.org/10.1136/bmjopen-2014-006677>).

Received 22 September 2014
Revised 9 January 2015
Accepted 13 January 2015



CrossMark

¹Departments of Medicine and Pathology and Laboratory Medicine, Centre for Heart Lung Innovation, Providence Heart-Lung Institute at St Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada

²Department of Laboratory Medicine and Pathobiology, University of Toronto, Ontario, Canada

Correspondence to
Dr Marc A Sze;
Marc.Sze@hli.ubc.ca

ABSTRACT

Objectives: The present study assesses the relationship between contents of GD1 (glycerol dehydratase)-positive *Lactobacillus*, presence of *Lactobacillus* and the inflammatory response measured in host lung tissue in mild to moderate chronic obstructive pulmonary disease (COPD). We hypothesise that there will be a loss of GD1 producing *Lactobacillus* with increasing severity of COPD and that GD1 has anti-inflammatory properties.

Setting: Secondary care, 1 participating centre in Vancouver, British Columbia, Canada.

Participants: 74 individuals who donated non-cancerous portions of their lungs or lobes removed as treatment for lung cancer (normal lung function controls (n=28), persons with mild (GOLD 1) (n=21) and moderate (GOLD 2) COPD (n=25)).

Outcome measures: Primary outcome measure was GD1 positivity within each group and whether or not this impacted quantitative histological measures of lung inflammation. Secondary outcome measures included *Lactobacillus* presence and quantification, and quantitative histological measurements of inflammation and remodelling in early COPD.

Results: Total bacterial count ($p>0.05$) and prevalence of *Lactobacillus* ($p>0.05$) did not differ between groups. However, the GD1 gene was detected more frequently in the controls (14%) than in either mild (5%) or moderate (0%) COPD ($p<0.05$) samples. Macrophage and neutrophil volume fractions (0.012 ± 0.005 (mean \pm SD) vs 0.026 ± 0.017 and 0.005 ± 0.002 vs 0.015 ± 0.014 , respectively) in peripheral lung tissue were reduced in samples positive for the GD1 gene ($p<0.0035$).

Conclusions: A reduction in GD1 positivity is associated with an increased tissue immune inflammatory response in early stage COPD. There is potential for *Lactobacillus* to be used as a possible therapeutic, however, validation of these results need to be completed before an anti-inflammatory role of *Lactobacillus* in COPD can be confirmed.

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is a worldwide public health problem that affects approximately 10% of persons over

Strengths and limitations of this study

- Study performed directly on human lung tissue.
- Data show a novel potential mechanism for *Lactobacillus* in chronic obstructive pulmonary disease (COPD) pathogenesis.
- Patient population is well controlled and stratified between disease groups.
- *Lactobacillus* is tested directly on tissue avoiding potential contamination from the mouth and upper airways.
- Small number of total positive GD1 (glycerol dehydratase) samples.

40 years of age¹ and is predicted to become the fourth leading cause of death in the USA by 2020.² Previous studies have shown an association between the decline in forced expiratory volume in 1 s (FEV₁) and the infiltration of peripheral lung tissue by neutrophils, macrophages, CD4+ and CD8+ T cells, and B-cell lymphocytes that have an increasing tendency to form tertiary lymphoid follicles in lungs from persons with severe (GOLD 3) and very severe (GOLD 4) COPD.³ These data provide evidence that an innate and adaptive inflammatory immune response may be present, and initially begins in early grade COPD. However, what the target is for this adaptive immune response is not yet known. Evidence has been shown to support a potential autoimmune mechanism against elastin.⁴ However, others believe that it could be environmental causes such as bacteria that drive this immune response.⁵ Recently, several groups have suggested that the lung itself is not sterile and that there is a detectable bacterial microbiome present.^{6–10} They have also shown that this bacterial microbiome changes in COPD.^{7–9} It may be possible that some of these bacteria could be potential targets of the adaptive immune response observed in COPD while others, in contrast, may have beneficial roles.

One of these previous reports on the bacterial microbiome in lung tissue identified *Lactobacillus* as a potential bacteria that could discriminate between control lung tissue and COPD GOLD 4.⁹ In order to investigate how this might contribute to the pathogenesis of COPD, this study examines the host response to differences between *Lactobacillus*-positive and *Lactobacillus*-negative samples as well as on *Lactobacillus* spp, either positive or negative, for the bacterial glycerol dehydratase (GD1) gene. This gene is most commonly found on plasmids within the *Lactobacillus reuteri* and along with potassium and 1,2-propanediol converts glycerol to reuterin via a dehydration reaction mechanism.¹¹ Reuterin is a broad-spectrum antibiotic of which the mechanism of action is postulated to act via an oxidative stress mechanism.¹² Expansion of *Lactobacillus* is associated with a reduction in reuterin production,¹³ potentially due to quorum sensing. This means that less *Lactobacillus* will be able to convert glycerol to the broad-spectrum antibiotic reuterin when these bacteria are found in high abundance.^{14 15} Based on this information along with the previous findings within the lung tissue bacterial microbiome we hypothesise that there will be a loss of GD1-producing *Lactobacillus* with increasing severity of COPD and that GD1 has anti-inflammatory properties.

METHODS

Preliminary data sample group

Samples from these individuals were from a previously published study⁹ and the processing, tissue sampling methods and DNA extraction methods have already been published. Demographic information was also previously published but in brief it consisted of tissue from eight non-smokers, eight smokers and eight COPD GOLD 4. The non-smokers and smokers had normal lung function without obstruction. Their FEV₁ percentage predicted value was 88.8±13.4 and 94.3±15.3, respectively, while their FEV₁/forced vital capacity (FVC) was 80.80±4.82 and 76.65±5.07, respectively. The COPD GOLD 4 group had an FEV₁ of 15.4±2.4 and an FEV₁/FVC of 26.83±7.85. There was no significant difference between pack years smoked between the smokers (46.00±12.24) and COPD GOLD 4 group (38.83±14.97).

Early COPD group

Tissue collection

The methods used to collect and preserve lung tissue for both PCR and quantitative PCR (qPCR) are previously published.^{3 9 16 17} Briefly, lung tissue samples donated by 74 individuals, treated for lung cancer by either lobectomy or pneumonectomy, were entered into this study. All 74 individuals provided informed consent for the use of their lung tissue in this study under conditions approved by the appropriate committees of all the institutions involved. The postbronchodilator FEV₁ and FEV₁/FVC measurements made during the preoperative assessment of lung function were used to assign these

donated tissues to 'At Risk' controls (n=28), mild COPD (GOLD 1) (n=21) and moderate COPD (GOLD 2) (n=25). Three of the 74 individuals (2 in the control group and 1 in the GOLD 1 group) had used inhaled corticosteroids and all 74 were free from clinically apparent respiratory infection at the time of surgery. No recent antibiotic treatment information was recorded in these individuals.

Tissue processing

Following completion of the pathological examination, each lung specimen was inflated, frozen and stored at -80°C as previously described.^{3 9 17} The specimen was kept frozen on dry ice while being cut from apex to base into 2 cm thick slices and a drill press with a sharpened hollow cylinder removed cores of tissue from each lung slice. Two tissue cores were examined for 27/28 cases in the control group, 19/21 cases in the GOLD 1 and 25/25 cases in the GOLD 2 groups. In the remaining three individuals' samples only one tissue core was examined. Five series of 20 consecutive frozen sections were cut from each tissue core and sections 1-5, 8-12 and 14-18 were allocated for DNA extraction, and sections 6-7, 13 and 19-20 allocated to coded glass slides for histological staining.

qPCR for total bacteria and *Lactobacillus*

For all qPCR assays, a correction factor to account for plate variation was applied as described in the online supplementary material. A previously described assay was used to determine the total bacterial load and spanned the 16S hypervariable V2 region. One modification was made to the analysis in that total bacteria were expressed as 16S/ng of DNA instead of bacteria/Rpp40.⁹ The assay for total *Lactobacillus* has been previously reported and no modifications were made.^{9 18} The forward primer sequence was 5-ACG AGT AGG GAA ATC TTC CA-3 and the reverse primer sequence was 5-CAC CGC TAC ACA TGG AG-3, and was designed to target all species in the genera *Lactobacillus* and *Lactococcus*. The values for total *Lactobacillus* were expressed as a percentage of total 16S bacteria and were obtained from normalisation to total 16S (eg, (*Lactobacillus* value/16S value)×100). The standard curve formulas for both assays can be found in the online supplementary table S1.

PCR for GD1

A 40-cycle PCR was performed on all DNA samples and yielded an approximately 560 bp sized band resolved on a 1% agarose gel. The forward primer was 5-GTTCAGTCCGCCGCATATC-3 and for the reverse primer 5-GCCGCTCTTCGTGGATTTC-3. The cycling conditions have been published previously.¹⁹ If at least one of the two samples from an individual tested positive, then the individual was considered positive for bacteria containing the GD1 gene.

Quantitative histology

Sections on coded glass slides were stained for macrophages, neutrophils, eosinophils, natural killer (NK) cells, dendritic cells and follicular dendritic cells, B lymphocytes, CD8+ T lymphocytes and CD4+ T lymphocytes. A more detailed breakdown of the staining can be found in online supplementary table S2. ImagePro Plus software V. 4.0 (MediaCybernetics Inc, Bethesda, Maryland, USA) was used to compute the volume fraction (Vv) of the tissue taken up by specifically stained inflammatory cells in the small airway wall tissue, using established point counting methods.³ Intraobserver and interobserver error for the quantitative histology was assessed (see online supplementary figures S1 and S2) and there was a good correlation between both (R^2 of 0.9046 and 0.9485, respectively).

Data analysis

Data from a previously published data set that consisted of non-smokers (n=8), smokers (n=8) and COPD GOLD 4 (n=8)⁹ were first analysed for the prevalence of GD1. Subsequent analysis was performed on the current data set for the role of *Lactobacillus* in early COPD. A multivariate analysis was performed to assess associations between the bacterial load, relative abundance of *Lactobacillus*, inflammatory cell Vv and airway wall thickness. Where applicable, the mean±SD for the different groups was listed. Categorical data comparing the distribution of *Lactobacillus* detection through increasing disease severity and GD1 detection throughout GOLD stage utilised a χ^2 test. Analysis of GD1-positive versus GD1-negative samples utilised multiple comparisons and a Bonferroni correction was applied. All other data utilised the Student t test for significance testing. A p value of <0.05 was considered statistically significant unless otherwise stated due to Bonferroni correction. Multivariate analysis was performed and a correlation was considered significant if it was below a p value of 0.05.

RESULTS

Early COPD group demographics

Table 1 shows there was no significant difference in age, gender or smoking history between the three groups of individuals ($p>0.05$), and the difference in FEV₁/FVC

and FEV₁ percentage predicted shown in table 1 is consistent with their status as either control, mild or moderate COPD.

qPCR for total bacteria and *Lactobacillus*

Online supplementary table S3 displays the location breakdown within the lung of each respective tissue sample. There was no difference between the top, middle and lower thirds of the lung with respect to total bacteria (p values ranging from 0.30 to 0.90; see online supplementary table S4 and figure S3). Since no significant difference was found between the two samples from each individual they were averaged together for all subsequent analysis. There was no significant difference ($p>0.05$) between the sample groups based on total 16S/100 ng of DNA (see online supplementary figure S4). The control group had an average value of 22.0±21 (mean±SD), the GOLD 1 group had 20.9±13.2 and the GOLD 2 group had 15.5±16.8 16S/100 ng of DNA, respectively. There was also no difference in total bacteria with respect to any drug use ($p>0.05$; see online supplementary figure S5) or steroid use only (data not shown).

There was no significant difference between the three sample groups in the percentage of total *Lactobacillus* after Bonferroni correction ($p>0.05$; see online supplementary figure S6). The percentage of total *Lactobacillus* for the control group was 8.7%±15.0% (mean±SD), 2.5%±3.8% for the GOLD 1 group and 8.1%±11.6% for the GOLD 2 group. There was no difference in the relative abundance of *Lactobacillus* based on any drug use or steroid use only (data not shown). Further, there was no significant difference in clinical characteristics (lung function, smoking history, age and gender) between *Lactobacillus*-positive and *Lactobacillus*-negative individuals (see online supplementary table S5).

PCR for GD1

Preliminary data showed that there was a clear decrease in the prevalence of GD1-producing *Lactobacillus* in the COPD GOLD 4 lung tissue when compared to both the non-smoking and smoking controls ($p<0.05$; figure 1A). Following up on this data in the early COPD data set a total of 5/74 (7%) of samples tested positive for the GD1 gene and 4/5 (80%) of these individuals also

Table 1 Clinical characteristics of the sample groups (average±SD)

	Controls (n=28)	GOLD 1 (n=21)	GOLD 2 (n=25)
Age	65.7±9.6	66.0±8.9	63±9.2
Gender (M:F:unknown)	16:11:1	14:7:0	17:8:0
Smoking history (cigarette-years)	895.4±622.8	1061.8±410.5	945.0±555.7
FEV ₁ /FVC	77.4±4.9	64.3±4.3*	62.0±7.0†
FEV ₁ (percentage predicted)	100.0±12.5	89.9±9.0‡	69.0±6.6‡

* $p<0.0001$ between controls versus GOLD 1.

† $p<0.0001$ between controls versus GOLD 2.

‡ $p<0.0001$ between GOLD 1 versus GOLD 2.

FEV₁, forced expiratory volume in 1 s; FVC, forced vital capacity.




Figure 1 (A) GD1 (glycerol dehydratase) distribution in the preliminary data set displayed as a percentage; non-smokers (n=8), smokers (n=8), and chronic obstructive pulmonary disease (COPD) GOLD 4 (n=8), $p>0.05$ between groups. (B) GD1 distribution displayed as a percentage. The graph showing the percentage of GD1-positive individuals in controls, GOLD 1 and GOLD 2.

tested positive for *Lactobacillus*. There was a significant decrease in the individuals who tested positive for the GD1 gene as the disease severity increased ($p<0.05$; figure 1B). A total of 14% of individuals were positive for GD1 in the control group versus 5% and 0% in the GOLD 1 and GOLD 2 groups, respectively (figure 1B). There was no significant difference in steroid use, bronchodilator use or use of both types of drugs between those who were GD1 positive and those who were GD1 negative ($p>0.05$).

Quantitative histology

The two samples from each individual were averaged for the final Vv measurement data used for all inflammatory cells. A complete figure of the quantitative histology results by GOLD grade is in the online supplementary figure S7. The multivariate analysis on all the Vv small airway measurements as well as the total bacterial 16S and percentage of total *Lactobacillus* showed that the Vv of CD1a+ cells correlated with the percentage of total *Lactobacillus* ($r=0.27$, $p=0.038$; table 2). These CD1a+ dendritic cells were also positively correlated with CD35+ follicular dendritic cells ($r=0.39$, $p=0.009$) and CD8+ T cells ($r=0.27$, $p=0.04$). Total 16S bacterial load positively correlated with CD21+ follicular dendritic cells ($r=0.30$, $p=0.013$; table 2). These CD21+ follicular dendritic cells were also positively correlated with NK-1 cells ($r=0.32$, $p=0.013$). The strongest correlation from the

multivariate analysis was between CD4+ T cells and CD68+ macrophages ($r=0.44$, $p=0.001$).

The inflammatory cell Vv was then investigated between GD1-positive versus GD1-negative individuals (figure 2). There was a significant reduction in the Vv of CD68+ macrophages and neutrophils in GD1-positive versus GD1-negative groups ($p<0.0035$; figure 2B, C). This difference held, when only control samples were analysed, for CD68+ macrophages (see online supplementary figure S8, $p<0.05$) but not for neutrophils (PMN) (see online supplementary figure S9, $p>0.05$). There was no difference in inflammatory cell Vv in the small airways with steroid (data not shown) or with any drug use (see online supplementary figure S3).

DISCUSSION

The present results confirm earlier reports showing no difference in total bacteria within the microbiome between control and COPD lungs, and extend them by showing that this applies to tissue in mild to moderate COPD.^{7,9} It also shows that although no detectable difference in total *Lactobacillus* could be made between controls, GOLD 1 and GOLD 2 differences in the genotypic makeup of the *Lactobacillus* could be found in the loss of GD1 positivity in mild and moderate COPD. Furthermore, *Lactobacillus* was found to have a positive correlation with CD1a+ dendritic cells suggesting that *Lactobacillus* may influence the host response through

Table 2 Significant comparisons from multivariate analysis of all measurements made on lung tissue

All samples				
Variable	By variable	n	Significant probability	Correlation
CD1a+ dendritic cell	Lacto/total (16S)	60	0.038	0.268
CD21+ follicular dendritic cell	16S total	66	0.013	0.304
CD35+ follicular dendritic cell	CD1a+ dendritic cell	45	0.009	0.386
NK-1	CD21+ follicular dendritic cell	59	0.013	0.321
CD4 T cell	CD68+ macrophage	51	0.001	0.445
CD8 T cell	CD1a+ dendritic cell	56	0.046	0.268
CD79a+ B cell	CD4 T cell	51	0.039	0.290

NK, natural killer.




Figure 2 (A) Inflammatory cell volume fraction in GD1 (glycerol dehydratase)-positive and GD1-negative samples. No significant difference was seen between the adaptive immune cell Vv and GD1 ($p > 0.05$). A significant difference was seen in the Vv of macrophages and neutrophils based on GD1 positivity ($p < 0.0035$). (B) Small airway Vv of macrophages by GD1 positivity ($p < 0.0035$). (C) Small airway Vv neutrophils by GD1 positivity ($p < 0.0035$).

these cells. Finally, this study also shows that GD1-positive individuals have lower macrophage and neutrophil Vv than GD1-negative individuals. Overall, this data supports the hypothesis that GD1-positive *Lactobacillus* may have an anti-inflammatory role in the pathogenesis of COPD.

These observations are of particular interest because of a previous report by Forsythe *et al.*²⁰ who showed that in mice sensitised to albumin, oral treatment with GD1-positive *L. reuteri* prior to challenging their airways with albumin resulted in a reduction in macrophage and neutrophil infiltration into their lung tissue, and reduced the cellular and inflammatory mediator content of their bronchoalveolar lavage (BAL) fluid compared with controls treated with saline alone.²⁰ In addition, these investigators subsequently reported that the non-specific CD4 (+) CD25 (+) Foxp3 (+) regulatory T cells

exerted a potent immunoregulatory action on the response to challenge by a specific antigen.²¹ These observations clearly suggest the possibility that GD1-positive *Lactobacilli* induce immunoregulatory mechanisms capable of controlling the host immune response in mice. Our study builds on these previous observations by investigating *Lactobacillus* in human lung tissue, and is consistent with Forsythe *et al.*'s macrophage and neutrophil data.

The preliminary data that were investigated suggest that, as in GOLD 1 and GOLD 2 grade disease, GOLD 4 also has a significant reduction in GD1-positive individuals versus controls. This would imply that reduction in GD1 positivity occurs early on in disease and could be a contributing factor to the increased inflammation seen as disease progresses.³ More studies designed to investigate *Lactobacillus* across all grades of disease will need to

be completed to elucidate the true scope to which this genus can influence the progression of COPD.

Previous studies have shown that CD8+ T cells are important in the progression of COPD.²² The correlation between CD1a+ dendritic cells and CD8+ T cells along with the CD1a+ dendritic cell correlation with *Lactobacillus* provides a possible mechanism by which these bacteria may exert their action in COPD. Although, in the early COPD data set, there was a significant reduction in GD1-positive macrophage and neutrophil Vv when compared to the GD1-negative group, no correlations with macrophages or neutrophils could be found with respect to *Lactobacillus*. This suggests that the effect between these specific inflammatory cells and GD1-positive *Lactobacillus* may not be a simple linear correlation and may act through other inflammatory cells. Additionally, CD1a+ dendritic cells did not correlate with the other major cells that have been found to be important in COPD (macrophages, CD4 T cells and B cells).^{3 22 23} This also implies that *Lactobacillus* may not directly impact these cells in disease. However, since this study focused mostly on early COPD, it is possible that *Lactobacillus* do have an impact in later stages of the disease, but this study was not designed to examine this possible relationship.

There are some important limitations that need to be mentioned in this study. First, although there was a significant reduction in the Vv of macrophages and neutrophils between GD1-positive, and GD1-negative groups, the total number of positive samples was relatively small, and larger studies will need to be carried out in order to confirm these initial findings. Interestingly, the preliminary data set that was used for this study consisted of tissue samples from individuals other than those used in the early COPD data set and showed consistent data with respect to GD1 positivity: that there was a significant reduction in GD1 positivity as COPD increased in severity. Second, the tissue was obtained from patients with lung cancer, and even though tissue was obtained from areas well away from the tumour, the global bacterial load as well as the composition could have been affected. However, none of the percentage of total *Lactobacillus* values for the control, GOLD 1 and GOLD 2 groups are out of the range of what would be expected based on previous research on the bacterial microbiome in lung tissue.⁹ Third, although previous research has shown that there may be a difference between the bacterial microbiome when steroids are used,²⁴ there were very few individuals on steroids (n=3) in this patient population and, for this study, steroids probably had no effect on the reported findings. Fourth, although GD1 was analysed, reuterin was not directly measured in this study and the mechanism of action in which GD1 positivity exerts its anti-inflammatory effect may not be through this particular pathway. Further studies, aimed at investigating reuterin directly, will need to be performed to confirm that GD1 acts through this antibiotic to have anti-inflammatory effects within COPD.

Additionally, in vitro studies may be useful in elucidating cause and effect since these findings simply show interesting associations. Cause and effect is hard to differentiate from these types of studies and the GD1 *Lactobacillus* could simply be a bystander that disappears as these inflammatory processes take place.

As more information about how bacteria can influence and change our innate and adaptive immune system becomes known, it is becoming increasingly evident that many bacteria have beneficial effects that can positively influence our immune system.²⁵ Although the effect is small, these results provide preliminary evidence of the potential benefit of GD1-positive *Lactobacillus* in small airway inflammation in COPD. Future studies may show that it could be possible to utilise *Lactobacillus* with the GD1 gene as a clinical intervention to help reduce inflammation or as a prophylaxis in those with mild and moderate COPD.

Contributors MAS performed and designed the experiments, performed data analysis and wrote the first draft; SU performed the experiments; MWE procured tissue samples; JCH conceived the study and made intellectual contributions; and RGH conceived the study, procured tissue samples and made intellectual contributions.

Funding The study was supported by Merck external studies agreement IIS 38970 (UBC #F1038978), NIH #HL084948 and CIHR #CIF-97687. None of the agencies had any input into the study design; in collection, analysis and interpretation of the data; in writing of the report or in the decision to submit the report for publication.

Competing interests None.

Ethics approval University of British Columbia and St Paul's Hospital.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement Extra data can be accessed via the Dryad data repository at <http://datadryad.org/> with the doi:10.5061/dryad.pb830.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

REFERENCES

1. Bourbeau J, Tan WC, Benedetti A, *et al.* Canadian Cohort Obstructive Lung Disease (CanCOLD): fulfilling the need for longitudinal observational studies in COPD. *COPD* 2014;11:125–32.
2. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. *PLoS Med* 2006;3:e442.
3. Hogg JC, Chu F, Utokaparch S, *et al.* The nature of small-airway obstruction in chronic obstructive pulmonary disease. *N Engl J Med* 2004;350:2645–53.
4. Low TB, Greene CM, O'Neill SJ, *et al.* Quantification and evaluation of the role of antielastin autoantibodies in the emphysematous lung. *Pulm Med* 2011;2011:826160.
5. Sethi S, Evans N, Grant BJ, *et al.* New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. *N Engl J Med* 2002;347:465–71.
6. Erb-Downward JR, Thompson DL, Han MK, *et al.* Analysis of the lung microbiome in the "healthy" smoker and in COPD. *PLoS ONE* 2011;6:e16384.
7. Hilty M, Burke C, Pedro H, *et al.* Disordered microbial communities in asthmatic airways. *PLoS ONE* 2010;5:e8578.
8. Huang YJ, Kim E, Cox MJ, *et al.* A persistent and diverse airway microbiota present during chronic obstructive pulmonary disease exacerbations. *OMICS* 2010;14:9–59.

9. Sze MA, Dimitriu PA, Hayashi S, *et al.* The lung tissue microbiome in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2012;185:1073–80.
10. Segal LN, Alekseyenko AV, Clemente JC, *et al.* Enrichment of lung microbiome with supraglottic taxa is associated with increased pulmonary inflammation. *Microbiome* 2013;1:19.
11. Talarico TL, Dobrogosz WJ. Purification and characterization of glycerol dehydratase from *Lactobacillus reuteri*. *Appl Environ Microbiol* 1990;56:1195–7.
12. Schaefer L, Auchtung TA, Hermans KE, *et al.* The antimicrobial compound reuterin (3-hydroxypropionaldehyde) induces oxidative stress via interaction with thiol groups. *Microbiology* 2010;156 (Pt 6):1589–99.
13. Bauer R, du Toit M, Kossmann J. Influence of environmental parameters on production of the acrolein precursor 3-hydroxypropionaldehyde by *Lactobacillus reuteri* DSMZ 20016 and its accumulation by wine lactobacilli. *Int J Food Microbiol* 2010;137:28–31.
14. Casas IA, Dobrogosz WJ. Validation of the probiotic concept: *Lactobacillus reuteri* confers broad-spectrum protection against disease in humans and animals. *Microb Ecol Health Dis* 2000;12:247–85.
15. El-Ziney MG, Jakobsen M. Effectiveness of reuterin alone and in combination with nisin or other food contact surfaces sanitizers and cleaners for disinfection of stainless steel surfaces contaminated with *Escherichia coli* and *Listeria innocua*. *J Food Agric Environ* 2009;7:145–9.
16. Gosselink JV, Hayashi S, Elliott WM, *et al.* Differential expression of tissue repair genes in the pathogenesis of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2010;181:1329–35.
17. McDonough JE, Yuan R, Suzuki M, *et al.* Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. *N Engl J Med* 2011;365:1567–75.
18. Ferreira RB, Gill N, Willing BP, *et al.* The intestinal microbiota plays a role in *Salmonella*-induced colitis independent of pathogen colonization. *PLoS ONE* 2011;6:e20338.
19. Kinova Sepova H, Bilkova A. Isolation and identification of new lactobacilli from goatling stomach and investigation of reuterin production in *Lactobacillus reuteri* strains. *Folia Microbiol (Praha)* 2013;58:33–8.
20. Forsythe P, Inman MD, Bienenstock J. Oral treatment with live *Lactobacillus reuteri* inhibits the allergic airway response in mice. *Am J Respir Crit Care Med* 2007;175:561–9.
21. Karimi K, Inman MD, Bienenstock J, *et al.* *Lactobacillus reuteri*-induced regulatory T cells protect against an allergic airway response in mice. *Am J Respir Crit Care Med* 2009;179:186–93.
22. Paats MS, Bergen IM, Hoogsteden HC, *et al.* Systemic CD4+ and CD8+ T-cell cytokine profiles correlate with GOLD stage in stable COPD. *Eur Respir J* 2012;40:330–7.
23. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. *Lancet* 2004;364:709–21.
24. Pragman AA, Kim HB, Reilly CS, *et al.* The lung microbiome in moderate and severe chronic obstructive pulmonary disease. *PLoS ONE* 2012;7:1–10.
25. Pflughoeft KJ, Versalovic J. Human microbiome in health and disease. *Annu Rev Pathol* 2012;7:99–122.